HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target

Rein Therapeutics, Inc

Rein Therapeutics, Inc

RNTX

0.00

HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ: RNTX) with a Buy and maintains $8 price target.